The effect of urinary protein excretion in post-renal transplant recurrent nephrotic syndrome on basiliximab pharmacokinetics and pharmacodynamics in a pediatric patient.
A pharmacokinetic and pharmacodynamic study of Basiliximab therapy has not been reported in recurrent post-renal transplant nephrotic syndrome. We assessed the effect of urinary protein in a focal segmental glomerulosclerosis patient. We measured the serum concentrations of basiliximab as well as the rate of activated CD25-positive T lymphocytes at fixed intervals in nephrotic versus eight nonnephrotic pediatric post-renal transplant patients. A significant reduction in the antibody concentrations was observed in focal segmental glomerulosclerosis. The CD25 expression rate showed a similar trend to the pharmacokinetic data. We conclude that cases of massive urinary protein excretion need special care to maintain immunosuppression in renal transplant using Basiliximab.
Nagai
T
T
Department of Pediatrics, Nagoya Daini Red-Cross Hospital Kidney Center, Nagoya City, Japan. nagataku@nagaoya2.jrc.or.jp
Goto
Y
Y
Haba
T
T
Uchida
K
K
D000328:Adult; D000375:Aging; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077552:Basiliximab; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005923:Glomerulosclerosis, Focal Segmental / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D009404:Nephrotic Syndrome / Q000601:surgery / Q000652:urine*; D011507:Proteinuria; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012008:Recurrence
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab